 |
Top 8 Idiopathic Pulmonary Fibrosis startups
Updated: May 07, 2024 | Editor: Jason Kwon |
1
Country: Hong Kong | Funding: $401.3M
Insilico aims to apply artificial intelligence to extend human productive longevity and transform the pharmaceutical industry.
Insilico aims to apply artificial intelligence to extend human productive longevity and transform the pharmaceutical industry.
2
Country: USA | Funding: $295.5M
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
Endeavor is a clinical-stage company developing a best-in-class Hedgehog inhibitor for Idiopathic Pulmonary Fibrosis.
3
Country: USA | Funding: $272.5M
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
4
Country: USA | Funding: $145.6M
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
5
Country: USA | Funding: $22.3M
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
6
Country: Germany | Funding: €4.7M
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler.
VisionHealth supports patients with chronic lung diseases who are dependent on their inhaler.
8
Country: Germany
Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health.
Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health.
